EditorialTheEUGOGOConsensusStatementontheManagementofGraves'Orbitopathy:EquallyApplicabletoNorthAmericanCliniciansandPatientsTheEuropeangrouponGraves'orbitopathy(EUGOGO;www.
eugogo.
org)isamultidisciplinaryconsortiumofclinicianscommittedtoimprovingtheman-agementofpatientswiththeocularcomplicationsofGraves'disease.
ThegroupdevelopedaconsensusstatementonthemanagementofGraves'orbitopathy(GO)thatwasunveiledattheannualmeetingoftheEuropeanThyroidAssociationinLeipzig,Germany,inSeptember2007,andsimultane-ouslyappearsinthisissueofThyroidandintheEuropeanJournalofEndocrinology(1).
EUGOGOistobecommendedfortheireffortsthatreectaremarkabledegreeofinterna-tionalcooperationbyacademicendocrinologistsandoph-thalmologists.
Theauthorsrefertothedocumentasa''consensusstate-ment''byexpertsintheeld,ratherthanapracticeguideline.
Thisseemsappropriate,becausewhiletheEUGOGOgroupcanbecreditedwithhavingperformedthemajorityofran-domizedcontrolledtrials(RCTs)inthisarea,theyarenotofsufcientscopetosupportformalpracticeguidelines.
De-spitethis,thedocumentistimelyandshouldproveusefultoclinicianswhomanageGOpatients.
Theauthorsrightlyanticipatethatthedocumentwill''provideafocusforauditandresearch''andaidintheidenticationoftopicsforfutureRCTs.
Theconsensusstatementisscholarlyandconcise,andtherecommendationsaregenerallyapplicabletoNorthAmeri-can,aswellasEuropean,cliniciansandpatients.
Thegradedrecommendationsareappendedinthedocument,andtheevidencesupportingeachisdiscussedindetailinthebodyofthetext.
TheapplicationoftherecommendationsrequiresthatcliniciansmustrstsegregatetheirGOpatientsinto''mild,''''moderatetosevere,''or''sight-threatening''categories,anddeterminewhetherornotthediseaseisactive.
Sufcientde-tailsareprovidedwithinthetextregardingtheassessmentofdiseaseseverityandactivitytoallowclassicationintothesebroadcategories.
EUGOGOdoesnotadvocateusinganyde-tailedgradingorscoringsystemotherthantherelativelysimple''clinicalactivityscore''andspecicocularmeasure-mentstoassesstheseverityofthedisease.
Whilethisapproachmaynotideallycaptureallfeaturesofthedisease,ithasbeenvalidatedbythegroupinnumerousclinicalstudiesandshouldserveasthegoldstandardagainstwhichotherGOclassica-tionsystemsaremeasured.
ThedocumentwillserveasanespeciallyusefultoolforclinicianswhoalreadyhavesomeexpertiseinmanagingGOpatients.
OthersnotsoexperiencedbutencounterGOpa-tientsintheirpracticeareadvisedto''referpatientswithGO,exceptforthemildestcases,tocombinedthyroid–eyeclinicsforfurtherassessmentandmanagement.
''Whichreferralsshouldbemadeurgentlyandwhicharenonurgentiscare-fullyoutlinedinthetext.
TheproblematicaspectofthisrecommendationforcliniciansinNorthAmerica,however,isthatregionalGOconsultantsarefrequentlyophthalmolo-gistswhodonotworkincombinedthyroid–eyeclinics.
OneofthemanypositiveresultsstemmingfromtheinceptionofEUGOGOhasbeenthemandatoryestablishmentofacom-binedthyroid–eyeclinicwithineachoftheEuropeanmedicalcenterwishingtoparticipateintheconsortium.
OnlythroughthistypeofcooperationcanGOpatientsbenetfromthefullrangeofexpertiseneededtounderstandandmanageallaspectsofthisperplexingdisease.
Whilethevastmajorityoftherecommendationsseemtometobequitereasonableandbasedtotheextentpossibleonpertinentliterature,Idotakeissuewiththestatementthat''thetreatmentofchoiceformoderatetosevereandactiveGOispulsesofintravenousglucocorticoids(GCs).
''WhilesevereGOmaywarrantthisapproach,IremainreluctanttorecommendivGCstopatientswithonlymoderatedisease(i.
e.
,thosehavingonlyasinglefeaturethatwouldplacetheminthe''moderatetosevere''category,orafewfeaturesmeasuringjustabovemild).
MyconcernstemsbothfromreportsoffatalacuteliverfailureinfourGOpatientsduringorfollowingcompletionofivGCtreatment(2,3),andfromthenaturalhistoryofthediseaseshowingimprovementinthemajorityof(albeitunselected)patientswithinayears'time.
Fortunately,thefrequencyofhepatotoxicityappearstobeverylow;7ofapproximately800GOpatientstreatedinItalywithivGCssufferedsevereliverdamage,ofwhom3died(3).
BecausenocaseofliverfailurehasbeenreportedinGOpatientsreceiving<8gmethylprednisolone,thecon-sensusstatementindicatesthatthecumulativedoseinonecourseshouldbelessthanthisamountandspeciesthativGCsshouldonlybeadministeredincentersexperiencedinthistherapy.
Despitethis,therisk–benetratioforivGCsinpatientswithactivediseaseofonlymoderateseveritywhomightdoequallywellwithoralsteroidsorevencarefulTHYROIDVolume18,Number3,2008MaryAnnLiebert,Inc.
DOI:10.
1089=thy.
2008.
0034281observationandfrequentreassessmentseemstometobeweightedtowardthesideofunacceptablerisk.
Insummary,theconsensusstatementbyEUGOGOisatimelyandusefuldocumentthatcanbeupdatedasadditio-nalevidencefromfutureRCTsbecomesavailable.
TheEu-ropeangroupisproceedingwithmulticentertrialsthatwillallowrecruitmentoflargenumbersofpatientsintothesestudies.
Thisconsensusstatementbringstotheforeashort-cominginthecareofGOpatientsintheUnitedStates,namely,thatmanypatientsarenotcaredforinjointthyroid–eyeclinics.
Inaddition,endocrinologists,ophthalmologists,andotherswhoseeGOpatientsinthiscountryarenotyetorganizedtoperformmulticenterRCTs.
Thereis,how-ever,activityunderwaytoincreasecooperationbetweenthesegroupsandtoestablishtheimportantinfrastructureneededtoperformlargemulticenterGOtrialsinNorthAmerica.
Finally,whileevidence-basedguidelinesorconsensusstatementscanfacilitatedecisionmaking,managementmustbeultimatelyindividualizedandfocusedontheneedsanddesiresofthepatient.
Thisrequirestheapplicationofboththeartandscienceofmedicine,anddemandsthatthecli-nicianactivelylistenstoGOpatients,manyofwhomareunderstandablyapprehensiveandfrightened.
Compassio-natecounselingofpatientshouldincludewiderangingdis-cussionsonthenatureoftheconditionanditsnaturalhistory,aswellascustomizedtreatmentoptions.
Suchanapproachislikelytoimproveoutcomesofwhatisoftenahighlydistressingdisease.
References1.
BartalenaL,BaldeschiL,DickensonA,EcksteinA,Kendall-TaylorP,MarcocciC,etal.
2007ConsensusstatementoftheEuropeanGrouponGraves'Orbitopathy(EUGOGO)onthemanagementofGraves'orbitopathy.
Thyroid18:333–346.
2.
WeisselM,HauffW2000Acuteandfatalliverfailureafterhigh-doseglucocorticoidpulsetherapyinapatientswithsevereeyedisease.
Thyroid10:521.
3.
MarinoM,MorabitoBrunetteMR,BartalenaL,PincheraA,MarcocciC2004AcuteandsevereliverdamageassociatedwithintravenousglucocorticoidpulsetherapyinpatientswithGraves'ophthalmopathy.
Thyroid14:403–406.
—RebeccaBahn,M.
D.
President,AmericanThyroidAssociationConsultantinEndocrinology,MayoClinic282BAHN
DiyVM是一家成立于2009年的国人主机商,提供的产品包括VPS主机、独立服务器租用等,产品数据中心包括中国香港、日本大阪和美国洛杉矶等,其中VPS主机基于XEN架构,支持异地备份与自定义镜像,VPS和独立服务器均可提供内网IP功能。商家VPS主机均2GB内存起步,三个地区机房可选,使用优惠码后每月69元起;独立服务器开设在香港沙田电信机房,CN2线路,自动化开通上架,最低499元/月起。下面以...
易速互联怎么样?易速互联是国人老牌主机商家,至今已经成立9年,商家销售虚拟主机、VPS及独立服务器,目前商家针对美国加州萨克拉门托RH数据中心进行促销,线路采用BGP直连线路,自带10G防御,美国加州地区,100M带宽不限流量,月付299元起,有需要美国不限流量独立服务器的朋友可以看看。点击进入:易速互联官方网站美国独立服务器优惠套餐:RH数据中心位于美国加州、配置丰富性价比高、10G DDOS免...
爱用云互联怎么样?爱用云是一家成立于2018年的老牌商家旗下的服务器销售品牌,是正规持证IDC/ISP/IRCS商家,主要销售国内、中国香港、国外服务器产品,线路有腾讯云国外线路、自营香港CN2线路等,都是中国大陆直连线路,非常适合免备案建站业务需求和各种负载较高的项目,同时国内服务器也有多个BGP以及高防节点。专注为个人开发者用户,中小型,大型企业用户提供一站式核心网络云端服务部署,促使用户云端...
www.gogo.com为你推荐
云爆发云联惠是什么来的刘祚天DJ是什么职业?www.jjwxc.net有那个网站可以看书?百度关键词工具常见的关键词挖掘工具有哪些www.yahoo.com.hk香港的常用网站8090lu.com《8090》节目有不有高清的在线观看网站啊?javmoo.com找下载JAV软件格式的网站haole10.com空人电影网改网址了?www.10yyy.cn是空人电影网么99nets.com制作网络虚拟证件的网站 那里有呀?yinrentangWeichentang正品怎么样,谁知道?
解析域名 windows虚机 中文域名交易中心 greengeeks wavecom 10t等于多少g godaddy续费优惠码 12u机柜尺寸 京东云擎 debian源 新站长网 中国特价网 java空间 骨干网络 193邮箱 cdn联盟 699美元 域名评估 如何用qq邮箱发邮件 电信托管 更多